"Spezialisiert auf die Behandlung von Diabetes mellitus Typ 1 und Typ 2 sowie auf Gefäßkrankheiten, ambulantes und stationäres Fußbehandlungszentum,"

During the past decade, Zentrum für Diabetes und Gefäßerkrankungen conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 4 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Zentrum für Diabetes und Gefäßerkrankungen" #1 sponsor was "Boehringer Ingelheim" with 2 trials, followed by "Abbott Diabetes Care" with 1 trials sponsored, "Dompé Farmaceutici S.p.A" with 1 trials sponsored, "Medtronic Diabetes" with 1 trials sponsored and "ikfe-CRO GmbH" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Zentrum für Diabetes und Gefäßerkrankungen" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "IKFE Institute for Clinical Research and Development" with 1 trials as a collaborator and "ikfe-CRO GmbH" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Zentrum für Diabetes und Gefäßerkrankungen" are "Diabetes Mellitus, Type 2" (3 trials), "Diabetes Mellitus" (1 trials), "Diabetes Mellitus, Insulin-Dependent" (1 trials) and "Diabetes Mellitus, Type 1" (1 trials). Many other conditions were trialed in "Zentrum für Diabetes und Gefäßerkrankungen" in a lesser frequency.

Most popular intervention types in "Zentrum für Diabetes und Gefäßerkrankungen" are "Drug" (4 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Empagliflozin" (1 trials), "Insulin Pump (Medtronic Minimed Paradigm® VEO)" (1 trials), "Ladarixin" (1 trials) and "Metformin and Saxagliptin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Zentrum für Diabetes und Gefäßerkrankungen" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Zentrum für Diabetes und Gefäßerkrankungen". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Zentrum für Diabetes und Gefäßerkrankungen, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Zentrum für Diabetes und Gefäßerkrankungen, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".

Zentrum für Diabetes und Gefäßerkrankungen has several departments that took part in Clinical trials: "Institut für Diabetesforschung GmbH Münster" - 13 trials